Trump’s $500 ACA refunds offer immediate financial relief to some enrollees, but healthcare experts question whether they address the broader affordability challenges facing Americans. The post Trump’s $500 ACA Refunds: ‘We Shouldn’t Confuse a Check With a Healthcare Affordability Strategy’ appeared first on MedCity News.

North Immunology is going public in a reverse merger with Aethlon Medical. With eczema as the lead indication, the inflammation and immunology biotech aims to show its bispecific antibody offers efficacy and tolerability advantages over Sanofi’s immune disorder juggernaut, Dupixent. The post North Immunology Reverse Merger Comes With $180M for Next-Gen Inflammation Drug appeared first on MedCity News.

After a near-miss with her own breast cancer diagnosis, Ariel Ganz co-founded Arben Ventures, a precision health and longevity fund that has backed 83 early-stage startups in three years. The post How a Cancer Diagnosis Shaped This VC’s Precision Health Thesis appeared first on MedCity News.

Historically, warming and positioning have been addressed independently because, in many surgical procedures, they do not significantly interfere with one another. However, that’s not the case in most robotic-assisted surgeries. The post The Missing Link in Surgical Safety: Integrating Patient Warming and Positioning appeared first on MedCity News.

Novartis is acquiring a Sironax platform technology designed to transport a range of drug modalities across the protective blood-brain barrier. The deal comes as Novartis weathers several pipeline setbacks, including trial failures for neuroscience drug candidates. The post Novartis Gains a Way to Get Drugs Into the Brain, Buying Sironax Tech for $125M appeared first on MedCity News.

As Medicare Advantage denial rates climb, health systems are dropping plans and steering patients back to traditional Medicare. Pearl Health CEO Michael Kopko thinks the original Medicare Advantage bargain has broken down — and that the model may never have been as efficient as policymakers assumed. The post As MA Denial Rates Rise, Hospitals Are Betting on Traditional Medicare Instead appeared first on MedCity News.

Clinicians have a responsibility to understand the risks posed by AI chatbots and to inform teen patients, their parents and caregivers about them. The post AI Isn’t a Therapist, but Many Teens Are Treating It Like One appeared first on MedCity News.

Hospitals’ operating margins fell to 1.4% in July, down from 2.2% in May and June, according to new data from Kaufman Hall. The margin decrease was driven largely by a seasonal slowdown in elective surgeries and payer mix pressures. The post Hospital Margins Fell This Summer Amid Outpatient Slowdown, Data Shows appeared first on MedCity News.

The Series C funding round was from The General Partnership, Index Ventures, General Catalyst and Andreessen Horowitz. The post Thatch Secures $108M, Reaches $1B Valuation appeared first on MedCity News.

GSK is acquiring global rights to a T cell engager that Chimagen Biosciences developed to hit three targets. GSK believes this tri-specific approach could offer advantages over currently available drugs that hit two targets, but other big pharma companies are also developing trispecific antibodies. The post GSK Commits $750M to Get Chimagen’s Phase 1-Ready Drug for Multiple Myeloma appeared first on MedCity News.

Pharma leaders must take a “construction crew” mindset and start treating workforce development in the same manner as they do critical infrastructure. The post The Real Bottleneck in U.S. Pharma Reshoring Isn’t Factories – It’s Talent appeared first on MedCity News.

[Sponsored] A new white paper from LiveWorld highlights how AI tools for healthcare marketers fall short and what’s needed for more effective marketing strategies. The post How Human-Led AI Improves Healthcare Marketing Intelligence appeared first on MedCity News.

Nara Health’s funding was led by Khosla Ventures, with participation from Long Journey Ventures and Superior Studios.  The post Nara Health Secures $14M for Third Party Administration Platform appeared first on MedCity News.

Scholar Rock’s Isembyld isn’t the only FDA-approved therapy for spinal muscular atrophy, but it is the first one that directly targets muscle tissue. Isembyld is the first commercial product for Scholar Rock, which is also evaluating the antibody in other rare muscle disorders. The post Scholar Rock Drug Wins First-in-Class Approval in Rare Neuromuscular Disease appeared first on MedCity News.

If trust, transparency, and accountability remain core values in medicine, AI governance cannot be left to improvisation.  The post Shadow AI Is the Fastest Growing Force in Medicine, and Hospitals Are the Only Ones Who Can Control It appeared first on MedCity News.